We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast Shifts to Metabolic Health: A Durable Growth Path?
Read MoreHide Full Article
Medifast, Inc. (MED - Free Report) is moving beyond its traditional identity as a weight-loss company to establish itself as a leader in the expanding metabolic health market. The company highlighted a significant opportunity to deliver a reset aimed at improving metabolic health.
With more than 90% of U.S. adults considered metabolically unhealthy, this issue represents both a major public health concern and a rare opportunity to redefine how wellness is approached. Medifast’s mission and long-term growth strategy are closely aligned with addressing this widespread need.
At the same time, the rapid adoption of GLP-1 medications has transformed the weight-management landscape by offering effective appetite control and short-term weight reduction. However, these treatments are not a comprehensive long-term solution without sustained lifestyle changes. Studies suggest that up to 40% of weight loss associated with GLP-1 use comes from lean mass, while roughly 74% of users discontinue treatment within a year, frequently leading to significant weight regain.
Many weight-related challenges stem from underlying metabolic dysfunction, which medication alone cannot fully correct. Lasting improvements in health depend on preserving lean muscle during weight loss to support metabolic function. Medifast’s clinical approach is designed to tackle these root causes by reducing visceral fat, maintaining lean mass and improving overall body composition. Recent clinical data show that after 16 weeks, participants retained 98% of their lean mass, reduced visceral fat by 14%, and achieved measurable improvements in metabolic health beyond weight loss alone.
Additionally, Medifast plans to launch product innovations next year based on metabolic synchronization and next-generation ingredients, reinforcing its focus on science-based innovation. By building on its existing programs, the company aims to further distinguish itself beyond GLP-1-centric solutions through a combination of clinical credibility, personalized coaching and sustainable metabolic health outcomes, supported by continued coach training through 2026. Overall, this strategic evolution positions Medifast on a promising path for long-term growth.
Zacks Rundown for MED
Medifast’s shares have lost 29.5% in the past six months compared with the industry’s decline of 17.7%. MED currently carries a Zacks Rank #4 (Sell).
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.33, lower than the industry’s average of 1.04.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current and next fiscal-year earnings implies year-over-year declines of 158.7% and 5.6%, respectively.
Image Source: Zacks Investment Research
Better-Ranked Stocks to Consider
The Vita Coco Company, Inc. (COCO - Free Report) develops, markets and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa and the Asia Pacific. COCO currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Vita Coco's current fiscal-year sales and earnings implies growth of 18% and 15%, respectively, from the year-ago reported figures. Vita Coco delivered a trailing four-quarter earnings surprise of 30.4%, on average.
United Natural Foods, Inc. (UNFI - Free Report) distributes natural, organic, specialty, produce and conventional grocery and non-food products in the United States and Canada. At present, United Natural sports a Zacks Rank of 1.
The Zacks Consensus Estimate for United Natural’s current fiscal-year sales and earnings implies growth of 1% and 187.3%, respectively, from the year-ago reported figures. UNFI delivered a trailing four-quarter earnings surprise of 52.1%, on average.
McCormick & Company, Inc. (MKC - Free Report) manufactures, markets and distributes spices, seasoning mixes, condiments and other flavorful products to the food industry. MKC currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for McCormick's current fiscal-year sales and earnings implies growth of 1.6% and 2.4%, respectively, from the year-ago actuals. MNST delivered a trailing four-quarter earnings surprise of 2.2%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medifast Shifts to Metabolic Health: A Durable Growth Path?
Medifast, Inc. (MED - Free Report) is moving beyond its traditional identity as a weight-loss company to establish itself as a leader in the expanding metabolic health market. The company highlighted a significant opportunity to deliver a reset aimed at improving metabolic health.
With more than 90% of U.S. adults considered metabolically unhealthy, this issue represents both a major public health concern and a rare opportunity to redefine how wellness is approached. Medifast’s mission and long-term growth strategy are closely aligned with addressing this widespread need.
At the same time, the rapid adoption of GLP-1 medications has transformed the weight-management landscape by offering effective appetite control and short-term weight reduction. However, these treatments are not a comprehensive long-term solution without sustained lifestyle changes. Studies suggest that up to 40% of weight loss associated with GLP-1 use comes from lean mass, while roughly 74% of users discontinue treatment within a year, frequently leading to significant weight regain.
Many weight-related challenges stem from underlying metabolic dysfunction, which medication alone cannot fully correct. Lasting improvements in health depend on preserving lean muscle during weight loss to support metabolic function. Medifast’s clinical approach is designed to tackle these root causes by reducing visceral fat, maintaining lean mass and improving overall body composition. Recent clinical data show that after 16 weeks, participants retained 98% of their lean mass, reduced visceral fat by 14%, and achieved measurable improvements in metabolic health beyond weight loss alone.
Additionally, Medifast plans to launch product innovations next year based on metabolic synchronization and next-generation ingredients, reinforcing its focus on science-based innovation. By building on its existing programs, the company aims to further distinguish itself beyond GLP-1-centric solutions through a combination of clinical credibility, personalized coaching and sustainable metabolic health outcomes, supported by continued coach training through 2026. Overall, this strategic evolution positions Medifast on a promising path for long-term growth.
Zacks Rundown for MED
Medifast’s shares have lost 29.5% in the past six months compared with the industry’s decline of 17.7%. MED currently carries a Zacks Rank #4 (Sell).
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.33, lower than the industry’s average of 1.04.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current and next fiscal-year earnings implies year-over-year declines of 158.7% and 5.6%, respectively.
Image Source: Zacks Investment Research
Better-Ranked Stocks to Consider
The Vita Coco Company, Inc. (COCO - Free Report) develops, markets and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa and the Asia Pacific. COCO currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Vita Coco's current fiscal-year sales and earnings implies growth of 18% and 15%, respectively, from the year-ago reported figures. Vita Coco delivered a trailing four-quarter earnings surprise of 30.4%, on average.
United Natural Foods, Inc. (UNFI - Free Report) distributes natural, organic, specialty, produce and conventional grocery and non-food products in the United States and Canada. At present, United Natural sports a Zacks Rank of 1.
The Zacks Consensus Estimate for United Natural’s current fiscal-year sales and earnings implies growth of 1% and 187.3%, respectively, from the year-ago reported figures. UNFI delivered a trailing four-quarter earnings surprise of 52.1%, on average.
McCormick & Company, Inc. (MKC - Free Report) manufactures, markets and distributes spices, seasoning mixes, condiments and other flavorful products to the food industry. MKC currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for McCormick's current fiscal-year sales and earnings implies growth of 1.6% and 2.4%, respectively, from the year-ago actuals. MNST delivered a trailing four-quarter earnings surprise of 2.2%, on average.